GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ICU Medical Inc (NAS:ICUI) » Definitions » Debt-to-EBITDA

ICUI (ICU Medical) Debt-to-EBITDA : 6.27 (As of Mar. 2025)


View and export this data going back to 1992. Start your Free Trial

What is ICU Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ICU Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $61 Mil. ICU Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1,539 Mil. ICU Medical's annualized EBITDA for the quarter that ended in Mar. 2025 was $255 Mil. ICU Medical's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was 6.27.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ICU Medical's Debt-to-EBITDA or its related term are showing as below:

ICUI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.19   Med: 3.3   Max: 9.05
Current: 5.74

During the past 13 years, the highest Debt-to-EBITDA Ratio of ICU Medical was 9.05. The lowest was 0.19. And the median was 3.30.

ICUI's Debt-to-EBITDA is ranked worse than
84.87% of 456 companies
in the Medical Devices & Instruments industry
Industry Median: 1.445 vs ICUI: 5.74

ICU Medical Debt-to-EBITDA Historical Data

The historical data trend for ICU Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ICU Medical Debt-to-EBITDA Chart

ICU Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.21 9.05 6.73 6.31

ICU Medical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.34 6.71 6.39 4.70 6.27

Competitive Comparison of ICU Medical's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, ICU Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ICU Medical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ICU Medical's Debt-to-EBITDA falls into.


;
;

ICU Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ICU Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(66.695 + 1574.967) / 260.041
=6.31

ICU Medical's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(61.285 + 1539.141) / 255.208
=6.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


ICU Medical  (NAS:ICUI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ICU Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ICU Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ICU Medical Business Description

Traded in Other Exchanges
N/A
Address
951 Calle Amanecer, San Clemente, CA, USA, 92673
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Executives
Christian B. Voigtlander officer: Chief Operating Officer 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
David C. Greenberg director 951 CALLE AMANECER, SAN CLEMENTE CA 92887
Vivek Jain director, officer: Chairman and CEO ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Daniel Woolson officer: VP, GM-Infusion Capital ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Virginia Ruth Sanzone officer: VP, General Counsel 951 CALLE AMANECER, SAN CLEMENTE CA 92673
George A Lopez director, officer: Chairman, other: Chairman C/O ICU MEDICAL, 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Smiths Group International Holdings Ltd 10 percent owner C/O SMITHS GROUP PLC, 11-12 ST. JAMES'S SQUARE, 4TH FLOOR, LONDON X0 SW1Y 4LB
Group Plc Smiths 10 percent owner 765 FINCHKEY ROAD, LONDON X0 00000
William Seeger director 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Kolleen T Kennedy director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Robert S Swinney director C/O ICU MEDICAL, 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Laurie Hernandez director 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Brian Michael Bonnell officer: Chief Financial Officer ICU MEDICAL INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Scott E Lamb officer: Controller ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673